Thermo Fisher Scientific has signed a definitive agreement to purchase Life Technologies for $76.00 in cash per fully diluted common share, or $13.6bn, plus the assumption of net debt at close ($2.2 billion as of year end 2012).
The acquisition is expected to strengthen the technology portfolio of Thermo Fisher and enables it to serve in applied markets and other fields including research and specialty diagnostics.
ThermoFisher Scientific president and chief executive officer Marc Casper said the acquisition of Life Technologies will enhance the company's growth strategy including technological innovation, a unique customer value proposition and expansion in emerging markets.
"We are extremely excited about this transaction because it creates the ultimate partner for our customers and significant value for our shareholders," Casper added.
"Our customers in research and applied markets will now be able to achieve even higher levels of innovation and productivity by working with the combined company."
The acquisition, which is expected to close early in 2014, is subject to a Life shareholder vote and satisfying customary closing conditions including regulatory approvals.